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Abstract: BACKGROUND: Until now, high-sensitivity cardiac troponin (hs-cTn) assays were mainly
developed for large central laboratory platforms. OBJECTIVES: This study aimed to assess the clinical
performance of a point-of-care (POC)-hs-cTnI assay in patients with suspected myocardial infarction
(MI). METHODS: This study enrolled patients presenting to the emergency department with symp-
toms suggestive of MI. Two cardiologists centrally adjudicated the final diagnosis using all clinical data
including cardiac imaging. The primary objective was to directly compare diagnostic accuracy of POC-
hs-cTnI-TriageTrue versus best-validated central laboratory assays. Secondary objectives included the
derivation and validation of a POC-hs-cTnI-TriageTrue-specific 0/1-h algorithm. RESULTS: MI was the
adjudicated final diagnosis in 178 of 1,261 patients (14%). The area under the curve (AUC) for POC-
hs-cTnI-TriageTrue at presentation was 0.95 (95% confidence interval [CI]: 0.93 to 0.96) and was at least
comparable to hs-cTnT-Elecsys (AUC: 0.94; 95% CI: 0.93 to 0.96; p = 0.213) and hs-cTnI-Architect
(AUC: 0.92; 95% CI: 0.90 to 0.93; p < 0.001). A single cutoff concentration <3 ng/l at presentation
identified 45% of patients at low risk with a negative predictive value (NPV) of 100% (95% CI: 99.4%
to 100%). A single cutoff concentration >60 ng/l identified patients at high risk with a positive predic-
tive value (PPV) of 76.8% (95% CI: 68.9% to 83.6%). The 0/1-h algorithm ruled out 55% of patients
(NPV: 100%; 95% CI: 98.8% to 100%), and ruled in 18% of patients (PPV: 76.8%; 95% CI: 67.2% to
84.7%). Ruled-out patients had cumulative event rates of 0% at 30 days and 1.6% at 2 years. This study
confirmed these findings in a secondary analysis including hs-cTnI-Architect for central adjudication.
CONCLUSIONS: The POC-hs-cTnI-TriageTrue assay provides high diagnostic accuracy in patients with
suspected MI with a clinical performance that is at least comparable to that of best-validated central
laboratory assays. (Advantageous Predictors of Acute Coronary Syndromes Evaluation Study [APACE];
NCT00470587).
DOI: https://doi.org/10.1016/j.jacc.2019.12.065
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ABSTRACT
BACKGROUND Until now, high-sensitivity cardiac troponin (hs-cTn) assays were mainly developed for large central
laboratory platforms.
OBJECTIVES This study aimed to assess the clinical performance of a point-of-care (POC)-hs-cTnI assay in patients
with suspected myocardial infarction (MI).
METHODS This study enrolled patients presenting to the emergency department with symptoms suggestive of MI. Two
cardiologists centrally adjudicated the final diagnosis using all clinical data including cardiac imaging. The primary
objective was to directly compare diagnostic accuracy of POC-hs-cTnI-TriageTrue versus best-validated central laboratory
assays. Secondary objectives included the derivation and validation of a POC-hs-cTnI-TriageTrue–specific 0/1-h algorithm.
RESULTS MI was the adjudicated final diagnosis in 178 of 1,261 patients (14%). The area under the curve (AUC) for POC-
hs-cTnI-TriageTrue at presentation was 0.95 (95% confidence interval [CI]: 0.93 to 0.96) and was at least comparable to
hs-cTnT-Elecsys (AUC: 0.94; 95% CI: 0.93 to 0.96; p ¼ 0.213) and hs-cTnI-Architect (AUC: 0.92; 95% CI: 0.90 to 0.93;
p < 0.001). A single cutoff concentration <3 ng/l at presentation identified 45% of patients at low risk with a negative
predictive value (NPV) of 100% (95% CI: 99.4% to 100%). A single cutoff concentration >60 ng/l identified patients at
high risk with a positive predictive value (PPV) of 76.8% (95% CI: 68.9% to 83.6%). The 0/1-h algorithm ruled out 55%
of patients (NPV: 100%; 95% CI: 98.8% to 100%), and ruled in 18% of patients (PPV: 76.8%; 95% CI: 67.2% to 84.7%).
Ruled-out patients had cumulative event rates of 0% at 30 days and 1.6% at 2 years. This study confirmed these findings
in a secondary analysis including hs-cTnI-Architect for central adjudication.
CONCLUSIONS The POC-hs-cTnI-TriageTrue assay provides high diagnostic accuracy in patients with suspected MI
with a clinical performance that is at least comparable to that of best-validated central laboratory assays. (Advantageous
Predictors of Acute Coronary Syndromes Evaluation Study [APACE]; NCT00470587) (J Am Coll Cardiol 2020;75:1111–24)
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M
ore than 10 million patients
worldwide present to emergency
departments (ED) each year with
symptoms suggestive of myocardial infarc-
tion (MI) such as chest discomfort or angina
pectoris (1). For the diagnosis of MI, electro-
cardiography and cardiac troponin (cTn)
make up the diagnostic cornerstones and
complement clinical assessment (2,3).
The introduction of high-sensitivity car-
diac troponin (hs-cTn) assays made it
possible to reliably measure cTn concentra-
tions around the 99th percentile and in the
normal range (2), thereby increasing the
diagnostic accuracy and reducing the time to
diagnosis with the use of rapid hs-cTnT/I-
based triage algorithms (3,4). Among the
hs-cTnT/I-based rapid triage algorithms, the
hs-cTnT/I 0/1-h algorithms have been extensively
validated and seem to provide the best balance of
safety and efficacy (5,6). Accordingly, they are rec-
ommended with a Class I recommendation in current
clinical practice guidelines (6).
However, until now, successful clinical imple-
mentation of these rapid algorithms was restricted to
hospitals working with large central laboratory plat-
forms, as current hs-cTnT/I assays require measure-
ment in a large central laboratory platform (7).
Whereas point-of-care (POC) testing for cTnT/I has
also been available for several years and can reduce
the turnaround time as compared to the central lab-
oratory by 30 to 60 min depending on the efficacy of
the local laboratory work flow, previous POC-cTnT/I
assays had poor analytical and clinical sensitivity
(6). The clinical availability of a POC-hs-cTnT/I assay
would allow combining the medical and economic
advantages of POC testing with those of the hs-cTnT/I
0/1-h algorithms (4,6).
Several modifications of the original cartridge,
which included control of sample flow and the
introduction of internal controls in each cartridge,
improved the analytical sensitivity and precision and
led to the development of the POC-hs-cTnI-
TriageTrue assay (TriageTrue High Sensitivity
Troponin I Test, Quidel Corporation, San Diego, Cal-
ifornia) (8). We aimed to assess the clinical perfor-
mance of the POC-hs-cTnI-TriageTrue assay in
patients with suspected MI. In addition, we sought to
define optimal cutoff concentrations at presentation
to identify patients at low or high risk and to derive
and validate an assay-specific 0/1-h algorithm for
ruling out and ruling in MI.
SEE PAGE 1125
ABBR EV I A T I ON S
AND ACRONYMS
AUC = area under the curve
CI = confidence interval
cTn = cardiac troponin
cTnT/I = cardiac troponin T
and/or I
CV = coefficient of variation
ED = emergency department




IQR = interquartile range
MI = myocardial infarction
NPV = negative predictive
value
POC = point-of-care
PPV = positive predictive value
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METHODS
STUDY DESIGN AND POPULATION. The APACE (Ad-
vantageous Predictors of Acute Coronary Syndromes
Evaluation) study is an ongoing prospective interna-
tional multicenter study that includes 12 centers in 5
countries and is aimed at advancing the early diag-
nosis of MI (NCT00470587) (3).
Adult patients presenting to the ED with symp-
toms suggestive of MI with an onset or peak
within the last 12 h were recruited. Although
enrollment was independent of renal function, we
excluded patients with terminal kidney failure on
chronic dialysis. The study was carried out accord-
ing to the principles of the Declaration of Helsinki
and was approved by the local ethics committees.
Written informed consent was obtained from all
patients.
For this analysis, we excluded patients with ST-
segment elevation MI, patients in whom the diag-
nosis remained unknown even after final adjudica-
tion and had at least 1 elevated hs-cTn concentration,
thereby possibly indicating MI, as well as patients
with missing measurements of the POC-hs-cTnI-
TriageTrue, hs-cTnT-Elecsys (Elecsys 2010 High-
Sensitivity Troponin T, Roche Diagnostics, Rotkreuz,
Switzerland) or hs-cTnI-Architect (ARCHITECT STAT
High-Sensitivity Troponin I, Abbott Laboratories,
Abbott Park, Illinois) assays. For the derivation and
validation of the 0/1-h algorithm, patients with
missing 1-h concentrations of POC-hs-cTnI-
TriageTrue were also excluded.
This study was designed and data were gathered
and analyzed according to the STARD (Standards
for Reporting of Diagnostic Accuracy Studies)
guidelines (9) (Online Table 1). Details on the
clinical assessment and the central adjudication of
the final diagnosis of patients is given in the
Online Appendix. In brief, 2 independent cardiolo-
gists performed the central adjudication of the
final diagnosis at the core laboratory (University
Hospital Basel) applying the universal definition
of MI (10).
INVESTIGATIONAL hs-cTn MEASUREMENTS. Blood
samples for determination of POC-hs-cTnI-
TriageTrue were collected in tubes containing ethyl-
enediaminetetraacetic acid plasma. Tubes containing
lithium heparin plasma or serum were used for the
hs-cTnI-Architect and hs-cTnT-Elecsys assays. Addi-
tional samples were collected at 1, 2, 3, and 6 h after
presentation. Serial sampling was discontinued when
a patient was discharged or transferred to the cath-
eter laboratory for treatment. After centrifugation,
samples were frozen at 80C until assayed in a
blinded fashion in a dedicated core laboratory.
According to the manufacturer, the POC-hs-cTnI-
TriageTrue assay on the Triage MeterPro System has
an overall 99th percentile concentration of 20.5 ng/l
(females 14.4 ng/l, males 25.7 ng/l) with a corre-
sponding coefficient of variation (CV) of 5.6% overall,
5.9% for females, and 5.4% for males (Online
Figure 1). Limits of blank, detection, and quantifica-
tion were determined to be 0.6 ng/l, 1.5 ng/l, and
2.1 ng/l for plasma, and 0.6 ng/l, 1.7 ng/l, and 2.8 ng/l
for whole blood, respectively. Seventy-two percent of
male and female normal patients in a healthy refer-
ence population had POC-hs-cTnI-TriageTrue con-
centrations above the limit of detection (Online
Figure 2, Online Table 2). The hs-cTnT-Elecsys assay
has a 99th percentile concentration of 14 ng/l with an




(n ¼ 178, 14%)
No MI
(n ¼ 1,083, 86%) p Value
Age, yrs 60 (47–73) 74 (61–81) 58 (46–70) <0.001
Female 409 (32) 47 (26) 362 (33) 0.064
Time since CPO, h 5 (2–12) 5 (2–12) 5 (2–12) 0.768
Early presenters, within 3 h after CPO 487 (39) 75 (42) 412 (38) 0.299
Risk factors
Hypertension 737 (58) 130 (73) 607 (56) <0.001
Hypercholesterolemia 665 (53) 129 (73) 467 (43) <0.001
Diabetes 214 (17) 45 (26) 169 (16) 0.001
Current smoking 314 (25) 38 (21) 276 (26) 0.232
History of smoking 477 (38) 87 (49) 390 (36) 0.001
History
Coronary artery disease 387 (31) 82 (46) 305 (28) <0.001
Previous MI 280 (22) 71 (40) 209 (19) <0.001
Previous revascularization 338 (27) 76 (43) 261 (24) <0.001
Peripheral artery disease 59 (5) 25 (14) 34 (3) <0.001
Previous stroke 81 (6) 19 (11) 62 (6) 0.020
ECG findings
Left bundle branch block 44 (4) 10 (6) 34 (3) 0.119
ST-segment depression 90 (7) 40 (23) 50 (5) <0.001
T-wave inversion 86 (7) 18 (10) 68 (6) 0.076
No significant ECG abnormalities 1,008 (80) 104 (58) 904 (84) <0.001
Body mass index, kg/m2 26 (24–29) 26 (24–29) 26 (24–30) 0.532
Laboratory findings
eGFR, ml/min/1.73 m2 85 (70–100) 75 (60–92) 86 (71–102) <0.001
Chronic medication
Aspirin 428 (34) 93 (52) 335 (31) <0.001
Vitamin K antagonists 146 (12) 27 (15) 119 (11) 0.106
Beta-blockers 405 (32) 72 (40) 333 (31) 0.010
Statins 436 (35) 87 (49) 349 (32) <0.001
ACE inhibitors/ARB 491 (39) 97 (55) 394 (36) <0.001
Calcium antagonists 197 (16) 42 (24) 155 (14) 0.002
Nitrates 114 (9) 31 (17) 83 (8) <0.001
Values are median (interquartile range) or n (%).
ACE ¼ angiotensin-converting-enzyme; ARB ¼ angiotensin receptor blockers; CPO ¼ chest pain onset;
ECG ¼ electrocardiogram; eGFR ¼ estimated glomerular filtration rate; MI ¼ myocardial infarction.
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imprecision corresponding to a CV of 10% at 13 ng/l.
Above 30 ng/l, the cTnT interassay CV were between
1% and 5% (2). The limits of blank and detection were
determined to be 3 ng/l and 5 ng/l, respectively (2).
The hs-cTnI-Architect assay has a 99th percentile
concentration of 26 ng/l with a corresponding CV of
10% at 5.6 ng/l (11). The limits of blank and detection
ranged from 0.7 to 1.3 ng/l and 1.1 to 1.9 ng/l,
respectively (11). The estimated glomerular filtration
rate was calculated using the abbreviated Modifica-
tion of Diet in Renal Disease formula (12).
SINGLE CUTOFF CONCENTRATIONS AT PRESENTATION
FOR RISK STRATIFICATION. We established the safety
of single cutoff concentrations at presentation,
quantified by the negative predictive value (NPV) and
sensitivity, to identify patients at low risk for MI. We
also established the accuracy, quantified by the pos-
itive predictive value (PPV) and specificity, to identify
patients at high risk for MI. Optimal cutoff concen-
trations for rule-out were pre-defined to achieve an
NPV and a sensitivity of $99.5% and $99%, respec-
tively. For the rule-in of MI, we pre-defined a PPV and
a specificity of $75% and $95%, respectively
(Online Figure 3A).
DERIVATION AND VALIDATION OF THE
POC-hs-cTnI-TriageTrue 0/1-H ALGORITHM. Using
the concept of the current European Society of Car-
diology (ESC) hs-cTnT/I 0/1-h algorithms (6) (Online
Figure 3B), the POC-hs-cTnI-TriageTrue 0/1-h algo-
rithm was developed in a derivation sample of
randomly (1:1 fashion) selected patients with avail-
able POC-hs-cTnI-TriageTrue measurements at ED
presentation and after 1 h. It was then directly
compared with the established ESC hs-cTnT/I 0/1-h
algorithms (Online Appendix).
FOLLOW-UP AND CLINICAL ENDPOINTS. Patients
were contacted at 3, 12, and 24 months after discharge
by telephone calls or in written form. We obtained
information regarding death during follow-up from
the patient’s hospital records, the family physician’s
records, and the national death registry. The co–
primary prognostic endpoints were cumulative
event rates at 30 days and at 2 years. The secondary
prognostic endpoint was major adverse cardiac
events defined as the composite of all-cause mortal-
ity, MI including index events, cardiogenic shock,
ventricular tachyarrhythmias, or higher-degree
atrioventricular block at 30 days.
















POC–hs–cTnI, AUC 0.95 (95% CI, 0.93–0.96)
hs–cTnT–Elecsys, AUC 0.94 (95% CI, 0.93–0.96)
hs–cTnI–Architect, AUC 0.92 (95% CI, 0.90–0.93)
















POC–hs–cTnI, AUC 0.94 (95% CI, 0.92–0.96)
hs–cTnT–Elecsys, AUC 0.93 (95% CI, 0.91–0.96)
hs–cTnI–Architect, AUC 0.90 (95% CI, 0.87–0.94)
0.0 0.2 0.4 0.6 0.8 1.0
1 -Specificity
Receiver-operating characteristic curves describing the diagnostic performance of the 3 high-sensitivity cardiac troponin (hs-cTn) assays at presentation
for the diagnosis of myocardial infarction (MI) in (A) all patients and (B) patients presenting early with chest pain onset within the last 3 h. AUC ¼ area
under the curve; CI ¼ confidence interval; cTnI (T) ¼ cardiac troponin I (T); POC ¼ point of care.
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STATISTICAL ANALYSIS. For the primary analysis,
we used serial hs-cTnT-Elecsys concentrations as
part of the study-specific dataset in the final adju-
dication. For the secondary sensitivity analysis, we
used serial hs-cTnI-Architect concentrations as part
of the study-specific dataset in the final adjudica-
tion. Receiver-operating characteristic curves were
constructed to assess the sensitivity and specificity
of the concentrations of the POC-hs-cTnI-
TriageTrue, hs-cTnT-Elecsys, and hs-cTnI-Architect
assays and to compare the ability of the respective
hs-cTn concentrations at ED presentation to di-
agnose MI. In addition, we used binary logistic
regression to combine POC-hs-cTnI-TriageTrue con-
centrations at ED presentation with early absolute
POC-hs-cTnI-TriageTrue changes. Accordingly, we
compared the ability of POC-hs-cTnI-TriageTrue
concentrations at 1, 2, and 3 h as well as absolute
1-, 2-, and 3-h changes and their combinations with
POC-hs-cTnI-TriageTrue concentrations at ED pre-
sentation to diagnose MI. We performed subgroup
analyses for patients presenting early (#3 h) and
late (>3 h) to the ED after chest pain onset or
maximum as well as for differences in sex.
Spearman correlations among POC-hs-cTnI-
TriageTrue, hs-cTnT-Elecsys, and hs-cTnI-Architect
were performed, and Bland-Altman plots were
constructed. Furthermore, we directly compared the
performance of the novel POC-hs-cTnI-TriageTrue
0/1-h algorithm with the current ESC hs-cTnT/I
0/1-h algorithms. The areas under the curves
(AUC), specifically receiver-operating characteristic
curves, were compared as recommended by DeLong
et al. (13).
To assess the diagnostic performance of the
assay’s 99th percentile, single POC-hs-cTnI-
TriageTrue cutoff concentrations, and the POC-hs-
cTnI-TriageTrue 0/1-h algorithm, safety was
assessed as the NPV and the sensitivity for MI in
the rule-out group. Accuracy was assessed as the
PPV and specificity for MI in the rule-in group, and
efficacy was quantified by the percentage of pa-
tients triaged toward ruling out or ruling in MI
either at presentation or within 1 h. We calculated
95% confidence intervals (CIs) for proportions by
bootstrapping with 1,000 resamples. Further details
are given in the Online Appendix.
All hypothesis testing was 2-tailed and p
values <0.05 were considered statistically significant.
Statistical analyses were performed using IBM SPSS
Statistics for Windows version 25.0 (IBM Corp.,
Armonk, New York) and MedCalc version 17.6 (Med-
Calc Software, Ostend, Belgium).
RESULTS
PATIENT CHARACTERISTICS. From February 2011 to
September 2014, 1,261 patients eligible for this anal-
ysis were enrolled (Online Figure 4). Thirty-nine
percent of patients presented to the ED within the
first 3 h after the onset of chest pain. The median age
was 60 years (interquartile range [IQR]: 47 to 73
years), and 32% were female (Table 1, Online Table 3).
ADJUDICATED FINAL DIAGNOSIS. The adjudicated
final diagnosis was MI in 178 of 1,261 patients (14%);
unstable angina in 113 of 1,261 (9%); cardiac symp-
toms of origin other than coronary artery disease such
as tachyarrhythmia, Takotsubo syndrome, heart fail-
ure, or myocarditis in 208 of 1,261 (17%); noncardiac
symptoms in 714 of 1,261 (57%); and unknown in 48 of
1,261 (4%).
CONCENTRATIONS AT PRESENTATION ACCORDING
TO FINAL DIAGNOSES. POC-hs-cTnI-TriageTrue
concentrations were higher in patients with MI than
in patients with other final diagnoses (p < 0.001). The
median POC-hs-cTnI-TriageTrue concentrations were
TABLE 2 Diagnostic Accuracy of POC-hs-cTnI-TriageTrue for
Single Concentrations, Absolute Changes, and Their Combination
During Serial Sampling
Time Point of Hs-cTnI ROC AUC (95% CI)
Presentation 0.95 (0.93–0.96)
After 1 h 0.97 (0.95–0.98)
After 2 h 0.97 (0.96–0.99)
After 3 h 0.98 (0.97–0.99)
Delta 1 h 0.81 (0.75–0.87)
Delta 2 h 0.82 (0.76–0.88)
Delta 3 h 0.92 (0.84–0.99)
Presentation and delta 1 h 0.97 (0.96–0.98)
Presentation and delta 2 h 0.97 (0.96–0.99)
Presentation and delta 3 h 0.99 (0.98–0.99)
Delta values refer to the absolute (unsigned) change between the level of hs-cTnI
at baseline and after 1, 2, or 3 h, respectively.
AUC ¼ area under the curve; hs-cTnI ¼ high-sensitivity cardiac troponin I;
POC ¼ point-of-care; ROC ¼ receiver-operating characteristic curve.












0 h 79.8 (73.1–85.4) 96.5 (95.2–97.6) 92.3 (90.6–93.9) 63.1 (56.4–69.4)
1 h 86.4 (79.8–91.5) 97.7 (96.5–98.6) 91.3 (89.3–93.0) 60.8 (53.8–67.4)
2 h 91.6 (85.1–95.9) 98.6 (97.5–99.3) 90.6 (88.4–92.6) 59.6 (52.1–66.7)
3 h 93.0 (80.9–98.5) 98.9 (96.7–99.8) 88.7 (84.5–92.1) 54.8 (42.7–66.5)
CI ¼ confidence interval; NPV ¼ negative predictive value; PPV ¼ positive predictive value.
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(A) Performance of single cutoff concentrations at presentation of POC-hs-cTnI-TriageTrue to identify patients at low risk for MI. (B) Performance of single cutoff
concentrations at presentation of POC-hs-cTnI-TriageTrue to identify patients at high risk for MI. Abbreviations as in Figure 1.
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109 ng/l (IQR: 25 to 425 ng/l) in patients with MI,
6.2 ng/l (IQR: 3.8 to 14.3 ng/l) in those with unstable
angina, 5.9 ng/l (IQR: 2.7 to 17.8 ng/l) in cardiac non-
coronary artery disease, 2.1 ng/l (IQR: 1.2 to 4.0 ng/l) in
noncardiac disease, and 3.3 ng/l (IQR: 2.1 to 5.2 ng/l)
in patients with an unknown diagnosis (Online
Figure 5A).
DIAGNOSTIC ACCURACY FOR MI AND DIAGNOSTIC
PERFORMANCE OF THE 99TH PERCENTILE AT
DIFFERENT TIME POINTS. The diagnostic accuracy of
measurements obtained at presentation, quantified
by AUC, of the POC-hs-cTnI-TriageTrue assay was
0.95 (95% CI: 0.93 to 0.96), 0.94 (95% CI: 0.93 to 0.96;
p ¼ 0.213) for hs-cTnT-Elecsys, and 0.92 (95% CI: 0.90
to 0.93; p < 0.001) for hs-cTnI-Architect (Figure 1A).
The AUC for POC-hs-cTnI-TriageTrue concentrations
at 1, 2, and 3 h were 0.97 (95% CI: 0.95 to 0.98), 0.97
(95% CI: 0.96 to 0.99), and 0.98 (95% CI: 0.97 to 0.99),
respectively (Table 2). The diagnostic performance of
the 99th percentile at the available time points is
shown in Table 3.
SUBGROUP ANALYSES ACCORDING TO TIME SINCE
CHEST PAIN ONSET AND SEX. Diagnostic accuracy at
presentation was high in all the pre-defined sub-
groups (Online Table 4). In early presenters (with
onset of chest pain within 3 h, 487 of 1,261, 39%), the
AUC for POC-hs-cTnI-TriageTrue was 0.94 (95% CI:
0.92 to 0.96), 0.93 (95% CI: 0.91 to 0.96; p ¼ 0.490) for
hs-cTnT-Elecsys, and 0.90 (95% CI: 0.87 to 0.94;
p ¼ 0.001) for hs-cTnI-Architect (Figure 1B).
OPTIMAL CUTOFF CONCENTRATIONS AT
PRESENTATION FOR RISK STRATIFICATION. A sin-
gle cutoff concentration of <3 ng/l met the pre-
defined NPV and sensitivity of $99.5% and $99%
for rule-out. Among 1,261 patients, 562 (45%) were
classified as low risk with a cumulative event rate of
0%. The NPV was 100% (95% CI: 99.4% to 100%), and
the sensitivity was 100% (95% CI: 98.0% to 100%)
(Figure 2A). When incorporating a safety criterion of
chest pain onset >3 h, the optimal single cutoff con-
centration was <4 ng/l. Thirty-three percent of pa-
tients were classified as low risk with a cumulative
event rate of 0%. The NPV was 100% (95% CI: 99.1%
to 100%), and the sensitivity was 100% (95% CI:
98.0% to 100%) (Online Figure 6). A single cutoff
concentration of >60 ng/l met the pre-defined PPV of
75% for rule-in. Among 1,261 patients, 138 (11%) were
classified as high risk with a cumulative event rate of
77% (106 of 138 patients with non–ST-segment
elevation MI). The PPV was 76.8% (95% CI: 68.9% to
83.6%), and the specificity was 97.1% (95% CI: 95.9%
to 98.0%) (Figure 2B). The performance of a single
cutoff strategy to identify low- and high-risk patients
is shown in Figure 3A.
DERIVATION OF THE POC-HS-cTnI-TriageTrue 0/1-H
ALGORITHM. Optimal thresholds for the rule-out
of MI were defined in the derivation cohort
(n ¼ 539) as either a POC-hs-cTnI-TriageTrue con-
centration <4 ng/l at presentation in patients with
an onset of chest pain >3 h (direct rule-out) or as a
POC-hs-cTnI-TriageTrue concentration <5 ng/l at
presentation and an absolute change <3 ng/l within
1 h for all patients (irrespective of time since chest
pain onset). Optimal cutoff criteria for the rule-in of
MI were defined as either a POC-hs-cTnI-TriageTrue
concentration $60 ng/l at presentation (direct rule-
in) or an absolute change $8 ng/l within 1 h.
Patients fulfilling neither of the above-mentioned
criteria for rule-out or for rule-in were classified
as observe. The diagnostic performance of the
POC-hs-cTnI-TriageTrue 0/1-h algorithm in the
derivation cohort is shown in Figure 3B and
Online Figure 7A.
VALIDATION OF THE POC-HS-cTnI-TriageTrue 0/1-H
ALGORITHM. By applying the derived cutoff criteria
to the internal validation cohort, 302 of 545 patients
(55%) could be classified as rule-out with a corre-
sponding NPV of 100% (95% CI: 98.8% to 100%) and a
sensitivity of 100% (95% CI: 95.9% to 100%)
(Figure 3C, Online Figure 7B). Direct rule-out based on
a single POC-hs-cTnI-TriageTrue concentration at
presentation was feasible in 164 of 545 patients
(30%). The POC-hs-cTnI-TriageTrue 0/1-h algorithm
classified 99 of 545 patients (18%) as rule-in with a
corresponding PPV of 76.8% (95% CI: 67.2% to 84.7%)
and a specificity of 95.0% (95% CI: 92.5% to 96.8%).
Direct rule-in based on a single POC-hs-cTnI-
TriageTrue concentration at presentation was
feasible in 66 of 545 patients (12%). Overall, the POC-
hs-cTnI-TriageTrue 0/1-h algorithm allowed a definite
triage decision after 1 h in 401 of 545 patients (73%;
either rule-out or rule-in). The remaining 144 of 545
patients (26%) were classified as observe with a
prevalence of MI of 8%.
DIRECT COMPARISON OF THE POC-hs-cTnI-
TriageTrue 0/1-H ALGORITHM WITH THE ESC 0/1-H
ALGORITHMS USING hs-cTnT-ELECSYS AND
hs-cTnI-ARCHITECT. The diagnostic performance of
the POC-hs-cTnI-TriageTrue 0/1-h algorithm was
similar to that of the hs-cTnT-Elecsys and the
hs-cTnI-Architect 0/1-h algorithms (Online Appendix,
Online Figures 8 and 9). The efficacy for direct rule-out
or rule-in based on the 0-h sample alone was 43%
(95% CI: 40% to 46%) for the POC-hs-cTnI-TriageTrue
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(A) Performance of POC-hs-cTnI-TriageTrue single cutoff concentrations at presentation in the overall population to identify patients at low or high risk.
Performance of the POC-hs-cTnI-TriageTrue 0/1-h algorithm in the (B) derivation cohort and (C) validation cohort. Delta 1 h denotes absolute (unsigned)
change of hs-cTnI within 1 h. *If chest pain onset >3 h before presentation to the emergency department. NPV ¼ negative predictive value; NSTEMI ¼ non–
ST-segment elevation myocardial infarction; PPV ¼ positive predictive value; Sens ¼ sensitivity; Spec ¼ specificity; other abbreviations as in Figure 1.
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0/1-h algorithm and was, therefore, even higher
than the 25% (95% CI: 22% to 27%) of hs-cTnT-
Elecsys and the 22% (95% CI: 20% to 25%) of
hs-cTnI-Architect.
PROGNOSTIC PERFORMANCE OF THE
POC-hs-cTnI-TriageTrue 0/1-h ALGORITHM. The
median follow-up was 727 days (IQR: 376 to 756 days)
with 5 deaths (3 cardiovascular) occurring within
30 days and 44 deaths (21 cardiovascular) within 2
years. The cumulative 30-day event rates were 0% (0
events), 1.1% (3 events), and 1.2% (2 events; log rank,
p ¼ 0.026) in the rule-out, observe, and rule-in
groups, respectively. At 2 years, the cumulative
event rates were 1.6% (8 events), 10.2% (21 events),
and 11.4% (15 events), respectively (log rank,
p < 0.001) (Figure 4).
CUMULATIVE MAJOR ADVERSE CARDIAC EVENTS
AT 30 DAYS. The cumulative major adverse cardiac
events rate (including the index event) was 0.2% (1
event) at 30 days in patients triaged to rule-out, 12.5%
(35 events) in patients triaged to observe, and 75.3%
(122 events) in patients triaged to rule-in by the POC-
hs-cTnI-TriageTrue 0/1-h algorithm (log
rank, p < 0.001).
SENSITIVITY ANALYSIS. Overall, the sensitivity
analysis with final diagnoses according to the final
adjudication including hs-cTnI-Architect concentra-
tions revealed similar findings and thereby confirmed
the findings from the primary analysis (Online
Appendix, Online Figures 5B and 9 to 11).
CORRELATION OF POC-hs-cTnI-TriageTrue WITH
LABORATORY-BASED hs-cTn ASSAYS. POC-hs-cTnI-
TriageTrue concentrations at ED presentation showed
high correlation with hs-cTnT-Elecsys (r ¼ 0.829;
p < 0.001) and hs-cTnI-Architect (r ¼ 0.844;
p < 0.001) (Online Figure 12).
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Kaplan-Meier curves depicting cumulative event rates within 30 days and at 2 years according to the triage decision provided by the
POC-hs-cTnI 0/1-h algorithm. No. ¼ number; other abbreviations as in Figure 1.
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DISCUSSION
We performed a large prospective multicenter study
using central adjudication by 2 independent cardiol-
ogists to assess the clinical performance of POC-hs-
cTnI-TriageTrue in the early diagnosis of MI (Central
Illustration). We report 7 major findings:
First, the diagnostic accuracy of the POC-hs-cTnI-
TriageTrue assay was very high and at least compa-
rable to that provided by the best validated central
laboratory-based hs-cTnT-Elecsys and hs-cTnI-
Architect assays. This finding was consistent in the
overall population, as well as in early presenters.
Although the sample size was high enough to
demonstrate a statistically significant difference in
the AUC in favor of POC-hs-cTnI-TriageTrue, the dif-
ference observed was numerically small. It therefore
remains unclear whether this difference also is of
clinical significance. Second, a low single cutoff con-
centration of <3 ng/l at presentation identified nearly
one-half of patients as low risk with an NPV of 100%
(95% CI: 99.4% to 100%). No patient with an index
non–ST-segment elevation MI was missed. About 1
out of 10 patients was identified to be at high risk for
MI by a single cut off concentration above 60 ng/l at
presentation with a PPV of 76.8% (95% CI: 68.9% to
83.6%). Third, the use of POC-hs-cTnI-TriageTrue
allowed us to successfully derive a POC-hs-cTnI-
TriageTrue 0/1-h algorithm in the derivation cohort,
defined by either a POC-hs-cTnI-TriageTrue
concentration <4 ng/l at presentation in patients
with an onset of chest pain >3 h (direct rule-out) or a
POC-hs-cTnI-TriageTrue concentration <5 ng/l at
presentation and an absolute change <3 ng/l within
CENTRAL ILLUSTRATION Performance of the Point-of-Care High-Sensitivity Cardiac Troponin I TriageTrue Assay
in Patients With Suspected Myocardial Infarction
Boeddinghaus, J. et al. J Am Coll Cardiol. 2020;75(10):1111–24.
Diagnostic performance of the point-of-care (POC)–high-sensitivity cardiac troponin I (hs-cTnI)-TriageTrue assay in patients with suspected myocardial infarction (MI).
Using POC-hs-cTnI-TriageTrue single cutoff concentrations at presentation allow to identify patients at low or high risk of MI. An assay-specific 0/1-h algorithm can
promptly and safely rule out and accurately rule in MI in almost three-fourths of patients. Delta 1 h denotes absolute (unsigned) change of hs-cTnI within 1 h. *If chest
pain onset >3 h before presentation to the emergency department. NPV ¼ negative predictive value; NSTEMI ¼ non–ST-segment elevation myocardial infarction;
PPV ¼ positive predictive value; Sens ¼ sensitivity; Spec ¼ specificity.
J A C C V O L . 7 5 , N O . 1 0 , 2 0 2 0 Boeddinghaus et al.
M A R C H 1 7 , 2 0 2 0 : 1 1 1 1 – 2 4 Early Diagnosis of MI With Point-of-Care hs-cTnI
1121
1 h for all patients (irrespective of time since chest
pain onset) for triage to rule-out. Applying this POC-
hs-cTnI-TriageTrue 0/1-h algorithm in the internal
validation cohort demonstrated very high safety in
the rule-out zone with an NPV of 100% (95% CI:
98.8% to 100%) and a sensitivity of 100% (95% CI:
95.9% to 100%). In addition, the accuracy for rule-in
of MI was high with a PPV of 76.8% (95% CI: 67.2%
to 84.7%). The high safety of this approach is further
highlighted by the fact that both type 1 and type 2 MI
were included in this analysis. Fourth, the perfor-
mance of the POC-hs-cTnI-TriageTrue 0/1-h algorithm
was comparable to that of the established guideline-
recommended 0/1-h algorithms and was also similar
to their performance in previous studies (6,14).
However, the higher efficacy of the POC-hs-cTnI-
TriageTrue 0/1-h algorithm for direct triage toward
rule-out or rule-in is an advantage over the 0/1-h
algorithms using the hs-cTnT-Elecsys and hs-cTnI-
Architect assays. Based on a single POC-hs-cTnI-
TriageTrue concentration at presentation, 43%
(95% CI: 40% to 46%) of patients were either directly
ruled out or in for MI without the need for serial hs-
cTnI sampling. This proportion was higher than the
25% (95% CI: 22% to 27%) for hs-cTnT-Elecsys and
22% (95% CI: 20% to 25%) for hs-cTnI-Architect. Fifth,
the overall efficacy of the novel POC-hs-cTnI-
TriageTrue 0/1-h algorithm was high in that it
assigned almost three-fourths of patients to either
rule-out or rule-in zones within 1 h, and only one-
fourth of patients to the observe zone. Sixth, these
findings were confirmed in a sensitivity analysis us-
ing a secondary adjudication including serial hs-cTnI-
Architect concentrations. Therefore, the reference
standard applied in this large diagnostic study of
patients presenting with suspected MI seems to be
very stringent and robust (15). By adding a secondary
analysis that included hs-cTnI-Architect (rather than
hs-cTnT-Elecsys as in the primary analysis) in addi-
tion to the clinical and imaging data available for the
adjudication of the final diagnosis, the generaliz-
ability of our findings was further increased. Seventh,
the cumulative event rates in patients assigned to the
rule-out zone by the 0/1-h algorithm were 0% at
30 days and 1.6% at 2 years, further underscoring the
safety of early discharge from the ED for most pa-
tients classified as rule-out, with further outpatient
management as clinically appropriate.
These findings extend and corroborate previous
work on POC-cTn testing and may have substantial
medical and economic implications (16–19). With the
clinical availability of a POC-hs-cTnI-TriageTrue assay
with an at least comparable diagnostic accuracy to
the best-validated central laboratory hs-cTnT/I
assays and a very safe and highly efficacious POC-hs-
cTnI-TriageTrue 0/1-h algorithm, the time to diag-
nosis and to discharge from the ED can be expected to
reduce even further than currently achieved with
central laboratory–based hs-cTnT/I 0/1-h algorithms
(5,6,14,20,21). Moreover, it would allow extending the
use of the hs-cTnI 0/1-h algorithm to settings without a
central laboratory including smaller hospitals, ambu-
lances, and general practices.
To date, the major disadvantage in POC-cTn assays
has been the lack of high-sensitivity assays, matching
the analytical and clinical performance of central
laboratory testing (22,23). For example, a prospective
comparison in 261 chest pain patients of the AQT90-
flex POCT-cTnT assay reported an insufficient sensi-
tivity (68%) and also a higher number of analytically
false-positive results as compared to hs-cTnT-Elecsys
(23). To overcome the lack of sensitivity, 1 strategy
was to use POC-cTn in combination with a
formal clinical risk score (24). A recent prospective
diagnostic study of the POC-cTnI (i-Stat, Abbott
Laboratories) in combination with the T-MACS
(Troponin-only Manchester Acute Coronary Syn-
dromes) decision aid in 716 patients reported a very
high sensitivity (99%), but also required a 3-h sample
and had lower efficacy (31%) compared with the POC-
hs-cTnI-TriageTrue 0/1-h algorithm derived in this
study (24). However, with the introduction of POC
tests that have a similar sensitivity to that of central
laboratory hs-cTn assays, formal risk scores, and the
use of a 3-h sample in all patients might become un-
necessary (25).
Our findings are supported by encouraging data
from a recent pilot study of the new POC-I-Stat TnI-
Nx assay (Abbott Diagnostics), showing comparable
AUC versus hs-cTnI-Architect (26). Similarly, the
PATHFAST cTnI-II assay (LSI Medience Corporation;
Mitsubishi Chemical Europe, Dusseldorf, Germany),
which runs on a table device (weight 62 pounds,
width 13.5 inches, depth 22.4 inches, height 18.7
inches) demonstrated high sensitivity (27) as well as
diagnostic performance comparable to that of hs-
cTnI-Architect (28). In contrast to the PATHFAST
analyzer, the POC Triage system (Quidel) is much
smaller (weight 1.5 pounds, width 6.25 inches, depth
8.5 inches, height 2.75 inches), facilitating a broader
use such as in the ambulance or private practice (29).
Due to U.S. Food and Drug Administration regula-
tions, the clinical introduction of hs-cTnT/I assays as
well as the clinical implementation of rapid hs-cTnT/
I-based triage algorithms has been delayed in the
United States compared with in, for example, Europe.
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However, to date several hs-cTnT/I assays have
received U.S. Food and Drug Administration clear-
ance and multiple U.S. institutions have implemented
hs-cTnT/I-based rapid diagnostic algorithms using
U.S. Food and Drug Administration–approved assays
(J. Januzzi, December 2019).
STUDY LIMITATIONS. First, this study was conducted
in ED patients with symptoms suggestive of MI.
Further studies are required to quantify the utility of
rule-out and rule-in strategies in patients with either
a higher pre-test probability (e.g., in a coronary care
unit setting) or in patients with a lower pre-test
probability (e.g., in a general practitioner setting)
for MI. Second, the data presented were obtained
from a prospective diagnostic study. Studies applying
the diagnostic algorithms prospectively for clinical
decision making are warranted. Third, not all patients
with acute chest pain had a second set of laboratory
measurements at 1 h and later. The most common
reasons for missing blood samples were logistic issues
in the ED that precluded blood draw around the 1-h
window. This limitation is inherent to studies
enrolling consecutive patients and is very unlikely to
have affected the main findings of the present study.
Fourth, although we used a very stringent method-
ology to adjudicate the presence or absence of MI,
including central adjudication by experienced cardi-
ologists, we still may have misclassified a small
number of patients. This would invariably have led to
an underestimation of the true diagnostic accuracy of
the novel 0/1-h algorithm. Fifth, although all labora-
tory procedures were performed according to strin-
gent standardized operating procedures, human error
in the handling of the study-specific blood samples
may have occurred in a small number of samples
leading to incorrect results pertaining to an individ-
ual patient. This again would invariably have led to
an underestimation of the true diagnostic accuracy of
the novel POC-hs-cTnI-TriageTrue 0/1-h algorithm.
Sixth, we cannot generalize our findings to patients
with terminal kidney failure requiring dialysis,
because they were excluded from this study.
CONCLUSIONS
POC-hs-cTnI-TriageTrue provides very high diag-
nostic accuracy in patients with suspected MI. Its
clinical performance is at least comparable to that of
the 2 best-validated central laboratory assays. The
availability of POC-hs-cTnI-TriageTrue will further
facilitate the implementation of early triage algo-
rithms and thereby provide major benefits for pa-
tients and health care systems.
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